Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.33 million.

Financial Guidance

Management reiterates its full year 2023 financial guidance, as updated on May 8, 2023:

Anticipated DANYELZA® net product revenues expected to be between $80 million and $85 million;
Anticipated operating expenses expected to be between $115 million and $120 million;
Anticipated total annual cash burn expected to be between $40 million and $50 million; and
Cash and cash equivalents anticipated to support operations as currently planned into 2026.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.